Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
February, 2026
February 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
232425262728  
Steven AR Murphy: The Risk of Pulmonary Embolism in IV Stem Cell Therapy
Steven AR Murphy/LinkedIn
Oct 26, 2025, 09:30

Steven AR Murphy: The Risk of Pulmonary Embolism in IV Stem Cell Therapy

Steven AR Murphy, Medical Director at Concierge Medical Associates, reposted from World Mitochondria Society on LinkedIn:

“IV infusion of mesenchymal stem cells resulting in mitochondrial aggregation and pulmonary embolism! That is the risk of IV stem cell therapy. World Mitochondria Society highlights this REAL risk. Concierge Medical Associates and I work with teams all over the globe to educate about the potential of mitochondrial transfer and about the risks of PE from these therapies. I’m so glad the science is being presented in Germany! We need a meeting in the USA now before we see some seriously Wild West risks and poor outcomes! p.s. that autologous MSC or PRP you received, that’s a mitochondrial transfer….”

Quoting World Mitochondria Society‘s post:

“Development of Mitochondria-Based Therapeutic Strategies for Disease Treatment. Prof. Kosuke Kusamori (Tokyo University of Science, Japan) presented innovative research advancing the field of mitochondrial transplantation and organelle-based therapy. His team investigated the use of mitochondria isolated from mesenchymal stromal cells (C3H10T1/2) as bioenergetic therapeutics capable of restoring damaged tissues. These mitochondria demonstrated strong antioxidant, proliferative, and cytoprotective properties, particularly in models of acute liver injury.

However, Prof. Kusamori identified a critical barrier to clinical translation: mitochondrial aggregation following systemic administration, which can cause pulmonary embolism. His group developed a proprietary anti-aggregation modification, allowing for safe intravenous delivery, targeted accumulation in the liver, and significant reduction of hepatic injury markers (ALT, AST).

This breakthrough demonstrates that controlling the physicochemical properties of isolated mitochondria is essential to unlock their therapeutic potential, a decisive step toward safe and effective mitochondria-based treatments for inflammatory and ischemic diseases.
Thanks for these excellent study.”

Steven AR Murphy

Stay updated with Hemostasis Today.

Health Hematology Hemostasis Today Ischemic Diseases Kosuke Kusamori Medicine Mesenchymal Stem Cells Mitochondrial Aggregation Mitochondrial Transplantation Pulmonary embolism Steven AR Murphy thrombosis World Mitochondria Society
NewsFeed